US 11,923,060 B2
Authenticating, establishing and tracking eligibility of a patient to purchase an over-the-counter drug
Rama Penta, San Jose, CA (US); Jeffrey Brittain, Memphis, TN (US); William Hanisak, Pipersville, PA (US); Audrey Belkin, Whitehouse Station, NJ (US); and Steven Rusche, North Wales, PA (US)
Assigned to Bayer HealthCare LLC, Whippany, NJ (US)
Filed by Bayer HealthCare LLC, Indianola, PA (US)
Filed on Mar. 9, 2023, as Appl. No. 18/181,433.
Application 18/181,433 is a continuation of application No. 15/733,572, granted, now 11,636,935, previously published as PCT/IB2019/051638, filed on Feb. 28, 2019.
Claims priority of provisional application 62/637,598, filed on Mar. 2, 2018.
Prior Publication US 2023/0245744 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 20/10 (2018.01); G06Q 30/018 (2023.01); G06Q 30/0601 (2023.01); G16H 10/20 (2018.01)
CPC G16H 20/10 (2018.01) [G06Q 30/018 (2013.01); G06Q 30/0601 (2013.01); G16H 10/20 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A computing system configured to implement a server of a retailer for effecting an online sale of an over-the-counter (OTC) drug to a patient, the computing system comprising a memory configured to store computer-readable program code, and at least one processor configured to access the memory, and execute the computer-readable program code to cause the computing system to:
communicate with a client device or terminal to effect an online sale of the OTC drug to the patient;
redirect the client device or terminal to a backend platform in communication with the computing system for the backend platform to communicate with the client device or terminal to authenticate, and establish and track eligibility of the patient to purchase the OTC drug; and
receive a redirection of the client device or terminal back from the backend platform to complete the online sale of the OTC drug to the patient when eligibility of the patient is established, or cancel the online sale of the OTC drug to the patient when the patient is ineligible to purchase the OTC drug.